Omabit raised US$2 million in seed financing led by Bright Ventures. The San Francisco company builds AI tools that help life science teams analyze scientific evidence. Its platform connects internal genomic and clinical data with relevant published research.
Funding plans
The new capital will support platform development and expand scientific and engineering capacity. Omabit plans to integrate the technology into more research and development workflows. The company also aims to support broader adoption across life science companies.
Company context
Omabit is based in San Francisco. The company joined the Stanford StartX community in summer 2026. Elena Cassidy, PhD, is its CEO and co-founder.
What the platform does
Omabit brings fragmented study data into a common analytical environment. Scientists can ask questions in plain language and review results with traceability to the underlying evidence. New datasets can be incorporated as they become available.
The platform's initial users are clinical development, biomarker, and translational teams. They can examine differences in treatment response and compare findings with published studies and comparison datasets. The tools help refine patient selection, guide study design, and clarify evidence for regulatory discussions.